SEC Comment Letter 0000000000-24-012249 to TriSalus Life Sciences, Inc. (TLSI)
TriSalus Life Sciences, Inc.
Date: Nov. 4, 2024 · CIK: 0001826667 · Accession: 0000000000-24-012249
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282882
Letter
November 4, 2024 Mary Szela Chief Executive Officer TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, CO 80031 Re:TriSalus Life Sciences, Inc. Registration Statement on Form S-3 Filed October 29, 2024 File No. 333-282882 Dear Mary Szela: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Robert Augustin at 202-551-8483 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc:Matthew Browne
Show Raw Text
November 4, 2024
Mary Szela
Chief Executive Officer
TriSalus Life Sciences, Inc.
6272 W. 91st Ave.
Westminster, CO 80031
Re:TriSalus Life Sciences, Inc.
Registration Statement on Form S-3
Filed October 29, 2024
File No. 333-282882
Dear Mary Szela:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Robert Augustin at 202-551-8483 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:Matthew Browne